Dale Anthony Cumming

This inventor holds 8 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignees: Genetics Institute, Inc., Acton Biotech Consulting. Active years: 1998-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dale Anthony Cumming. Retrieved from https://idiyas.com/inventor/dale-anthony-cumming

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 4)

% Patents Active = 50.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 1

Average Co-Inventor Count = 4.1

ph-index = 5

Forward Citations = 202(Granted Patents)

Company Filing History:

7 out of 392

Genetics Institute, Inc.

patents

1 out of 1

Acton Biotech Consulting

patent

Years Active: 1998-2013

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8389793 - Methods for increasing the diversity of monoclonal antibodies produced against an antigen (2013-03-05),

2. 8232252 - P-selectin ligand protein (2012-07-31),

3. 7927835 - Nucleic acids encoding P-selectin ligand fusion proteins (2011-04-19),

4. 7563760 - P-selectin ligand protein (2009-07-21),

5. 6277975 - Fusions of P-selectin ligand protein and polynucleotides encoding same (2001-08-21),

6. 5843707 - Nucleic acid encoding a novel P-selectin ligand protein (1998-12-01),

7. 5840679 - Method of inhibiting P-selectin ligand activity (1998-11-24),

8. 5827817 - P-selectin ligand protein (1998-10-27),

Title: The Innovative Contributions of Dale Anthony Cumming

Introduction

Dale Anthony Cumming is a notable inventor based in Acton, MA (US), recognized for his significant contributions to the field of biotechnology. With a total of eight patents to his name, Cumming has made strides in developing methods and compositions that enhance the production of monoclonal antibodies and address inflammatory diseases.

Latest Patents

Cumming's latest patents include innovative methods for increasing the diversity of monoclonal antibodies produced against an antigen. This invention utilizes the immunization of a murine host that is defective in enzymes involved in post-translational modifications. The resulting monoclonal antibodies are unique and not produced when a normal mouse is immunized with the same antigen. Additionally, he has developed a novel P-selectin ligand glycoprotein, which includes specific amino acid sequences and DNA sequences encoding the protein. This invention also encompasses pharmaceutical compositions aimed at treating inflammatory diseases characterized by P-selectin and E-selectin-mediated intercellular adhesion.

Career Highlights

Throughout his career, Cumming has worked with prominent organizations such as Genetics Institute, Inc. and Acton Biotech Consulting. His work in these companies has contributed to advancements in biotechnology and therapeutic development.

Collaborations

Cumming has collaborated with notable colleagues, including Glenn R. Larsen and Dianne S. Sako, who have played a role in his innovative journey.

Conclusion

Dale Anthony Cumming's contributions to biotechnology through his patents and collaborations highlight his role as a significant inventor in the field. His work continues to influence advancements in medical treatments and therapeutic methods.

Profile summary based on public USPTO records.